Literature DB >> 33289503

Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.

Matteo Riva1,2, Roxanne Wouters1, Edmond Sterpin3, Roberto Giovannoni4, Louis Boon5, Uwe Himmelreich6, Willy Gsell6, Marc Van Ranst7, An Coosemans1,8.   

Abstract

BACKGROUND: The lack of immune synergy with conventional chemoradiation could explain the failure of checkpoint inhibitors in current clinical trials for high-grade gliomas (HGGs).
OBJECTIVE: To analyze the impact of radiotherapy (RT), Temozolomide (TMZ) and antiprogrammed cell death protein 1 (αPD1) (as single or combined treatments) on the immune microenvironment of experimental HGGs.
METHODS: Mice harboring neurosphere /CT-2A HGGs received RT (4 Gy, single dose), TMZ (50 mg/kg, 4 doses) and αPD1 (100 μg, 3 doses) as monotherapies or combinations. The influence on survival, tumor volume, and tumor-infiltrating immune cells was analyzed.
RESULTS: RT increased total T cells (P = .0159) and cluster of differentiation (CD)8+ T cells (P = .0078) compared to TMZ. Lymphocyte subpopulations resulting from TMZ or αPD1 treatment were comparable with those of controls. RT reduced M2 tumor-associated macrophages/microglia (P = .0019) and monocytic myeloid derived suppressor cells (mMDSCs, P = .0003) compared to controls. The effect on mMDSC was also seen following TMZ and αPD1 treatment, although less pronounced (P = .0439 and P = .0538, respectively). Combining RT with TMZ reduced CD8+ T cells (P = .0145) compared to RT alone. Adding αPD1 partially mitigated this effect as shown by the increased CD8+ T cells/Tregs ratio, even if this result failed to reach statistical significance (P = .0973). Changing the combination sequence of RT, TMZ, and αPD1 did not alter survival nor the immune effects.
CONCLUSION: RT, TMZ, and αPD1 modify the immune microenvironment of HGG. The combination of RT with TMZ induces a strong immune suppression which cannot be effectively counteracted by αPD1.
Copyright © 2020 by the Congress of Neurological Surgeons.

Entities:  

Keywords:  Combination therapies; Glioblastoma; High-grade glioma; Immunotherapy; PD1; Stereotactic radiotherapy; Temozolomide

Mesh:

Substances:

Year:  2021        PMID: 33289503     DOI: 10.1093/neuros/nyaa421

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  2 in total

Review 1.  Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End.

Authors:  Angeliki Datsi; Rüdiger V Sorg
Journal:  Front Immunol       Date:  2021-11-02       Impact factor: 7.561

2.  Multiple Irradiation Affects Cellular and Extracellular Components of the Mouse Brain Tissue and Adhesion and Proliferation of Glioblastoma Cells in Experimental System In Vivo.

Authors:  Maxim O Politko; Alexandra Y Tsidulko; Oxana A Pashkovskaya; Konstantin E Kuper; Anastasia V Suhovskih; Galina M Kazanskaya; Lyubov S Klyushova; Dmitry K Sokolov; Alexander M Volkov; Evgenii E Kliver; Alexander A Zheravin; Svetlana V Aidagulova; Elvira V Grigorieva
Journal:  Int J Mol Sci       Date:  2021-12-12       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.